The team is exploring whether biomarker testing could also identify patients who benefit more from immune checkpoint inhibitors after radiation.

The firm said it is in discussions with the FDA to resubmit its biologics license application seeking approval for Ebvallo.

After establishing dosing and safety in Phase I, researchers will evaluate the drug's anti-tumor activity in patients with PSMA-expressing cancers.